Expres2ion Biotechnologies ApS

https://www.expres2ionbio.com

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, ExpreS2, that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, ExpreS2ion develops novel VLP based vaccines through the joint venture AdaptVac ApS which was founded in 2017. *

	Start	2010-01-01 splitoff
	Group	Expres2ion Biotech (Group)
	Industry	gene expression technology
	Industry 2	ExpreS2 technology platform (Drosophila Schneider-2 cell based protein expression platform)
	Person	Dyring, Charlotte (ExpreS2ion Biotechnologies 201306 CEO before Pharmexa + Kabi Pharmacia)
	Person 2	Salgueiro, Sancha (ExpreS2ion Biotechnologies 201306 CBP Business Development before Novozymes + Diatos + Meristem)

	Region	Hørsholm
	Country	Denmark
	Street	1 Agern Allé SCION-DTU Science Park
	City	2970 Hørsholm
	Tel	+45-41-666-121
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: ExpreS2ion Biotech Holding AB. (7/1/19). "Press Release: ExpreS2ion Licenses Groundbreaking CRISPR/Cas9 Gene Editing Technology from ERS Genomics".

		Record changed: 2024-02-12